良性前列腺增生的病理生理学：该疾病药物治疗的见解
Pathophysiology of benign prostatic hyperplasia: insights from medical therapy for the disease.
作者信息
Lepor Herbert
机构信息
Department of Urology, New York University School of Medicine New York, NY.
出版信息
Rev Urol. 2009 Fall;11(Suppl 1):S9-S13.
Abstract
The medical treatment of benign prostatic hyperplasia (BPH) has its roots in the early 1970s. During this era, the first clinical trials investigating alpha-blockade and androgen deprivation therapy were reported for men with clinical BPH. The observation that clinical BPH was improved following administration of both alpha-blockers and androgen deprivation therapy supported the evolving paradigm that clinical BPH resulted from dynamic and static pathways. During the past several decades, the evolution of alpha-blockers for the treatment of BPH has been impacted by innovations targeted to simplify the administration and improve tolerability while maintaining their effectiveness.
摘要
良性前列腺增生（BPH）的医学治疗始于20世纪70年代初。在这个时期，首次报道了针对临床BPH男性的α受体阻滞剂和雄激素剥夺疗法的临床试验。服用α受体阻滞剂和雄激素剥夺疗法后临床BPH得到改善这一观察结果支持了不断发展的范式，即临床BPH是由动态和静态途径导致的。在过去几十年中，用于治疗BPH的α受体阻滞剂的发展受到了旨在简化给药并提高耐受性同时保持其有效性的创新的影响。
相似文献
1
Pathophysiology of benign prostatic hyperplasia: insights from medical therapy for the disease.良性前列腺增生的病理生理学：该疾病药物治疗的见解
Rev Urol. 2009 Fall;11(Suppl 1):S9-S13.
2
Alpha-blockers for the Treatment of Benign Prostatic Hyperplasia.用于治疗良性前列腺增生的α受体阻滞剂
Urol Clin North Am. 2016 Aug;43(3):311-23. doi: 10.1016/j.ucl.2016.04.009.
3
Monotherapy versus combination drug therapy for the treatment of benign prostatic hyperplasia.单药治疗与联合药物治疗良性前列腺增生症
Am J Geriatr Pharmacother. 2005 Jun;3(2):103-14. doi: 10.1016/s1543-5946(05)00031-0.
4
The role of combination medical therapy in benign prostatic hyperplasia.联合药物治疗在良性前列腺增生中的作用。
Int J Impot Res. 2008 Dec;20 Suppl 3:S33-43. doi: 10.1038/ijir.2008.51.
5
Current medical treatment of lower urinary tract symptoms/BPH: do we have a standard?当前下尿路症状/BPH 的医学治疗：我们有标准吗？
Curr Opin Urol. 2014 Jan;24(1):21-8. doi: 10.1097/MOU.0000000000000007.
6
Early treatment of benign prostatic hyperplasia: implications for reducing the risk of permanent bladder damage.良性前列腺增生的早期治疗：对降低永久性膀胱损伤风险的意义。
Drugs Aging. 2003;20(3):185-95. doi: 10.2165/00002512-200320030-00003.
7
Role of alpha-adrenergic blockers in the treatment of benign prostatic hyperplasia.α-肾上腺素能阻滞剂在良性前列腺增生治疗中的作用。
Prostate Suppl. 1990;3:75-84. doi: 10.1002/pros.2990170508.
8
Benign prostatic hyperplasia - progress in pathophysiology and management.良性前列腺增生——病理生理学与治疗进展
Pol Merkur Lekarski. 2015 Nov;39(233):263-70.
9
Emerging drugs for the treatment of benign prostatic hyperplasia.治疗良性前列腺增生的新型药物
Expert Opin Emerg Drugs. 2017 Sep;22(3):201-212. doi: 10.1080/14728214.2017.1369953. Epub 2017 Aug 30.
10
[Guide dedicated to general practitioner for the management of lower urinary tract symptoms related to benign prostatic hyperplasia].[全科医生管理良性前列腺增生相关下尿路症状指南]
Prog Urol. 2015 Jun;25(7):404-12. doi: 10.1016/j.purol.2015.02.008. Epub 2015 Apr 2.
引用本文的文献
1
Prostatic Artery Embolization: Technical Pearls.前列腺动脉栓塞术：技术要点
Semin Intervent Radiol. 2022 Dec 20;39(6):555-561. doi: 10.1055/s-0042-1759690. eCollection 2022 Dec.
2
Fall risk related to subtype-specific alpha-antagonists for benign prostatic hyperplasia: a nationwide Korean population-based cohort study.良性前列腺增生症特定亚型α-拮抗剂相关的跌倒风险：一项基于韩国全国人群的队列研究。
World J Urol. 2022 Dec;40(12):3043-3048. doi: 10.1007/s00345-022-04195-w. Epub 2022 Oct 31.
3
Comprehensive Review on Current Controversies and Debate in Prostate Artery Embolization.前列腺动脉栓塞术当前争议与辩论的综合综述
Turk J Urol. 2022 May;48(3):166-173. doi: 10.5152/tud.2022.21337.
4
Increased risk of subsequent benign prostatic hyperplasia in non-Helicobacter pylori-infected peptic ulcer patients: a population-based cohort study.非幽门螺杆菌感染消化性溃疡患者中良性前列腺增生风险增加：一项基于人群的队列研究。
Sci Rep. 2020 Dec 10;10(1):21719. doi: 10.1038/s41598-020-78913-y.
5
The Relationships between Thyroid Hormone Levels and Lower Urinary Tract Symptoms/Benign Prostatic Hyperplasia.甲状腺激素水平与下尿路症状/良性前列腺增生之间的关系
World J Mens Health. 2019 Sep;37(3):364-371. doi: 10.5534/wjmh.180084. Epub 2019 Jan 4.
6
α1-Blockers in Men with Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Obstruction: Is Silodosin Different?用于有提示良性前列腺梗阻的下尿路症状男性的α1阻滞剂：西洛多辛有何不同？
Adv Ther. 2017 Jan;33(12):2110-2121. doi: 10.1007/s12325-016-0423-5. Epub 2016 Oct 17.
7
Silodosin: treatment of the signs and symptoms of benign prostatic hyperplasia.西洛多辛：治疗良性前列腺增生的症状。
Drugs. 2011 May 7;71(7):897-907. doi: 10.2165/11204780-000000000-00000.
本文引用的文献
1
The QT Interval and Selection of Alpha-Blockers for Benign Prostatic Hyperplasia.QT间期与良性前列腺增生症α受体阻滞剂的选择
Rev Urol. 2008 Spring;10(2):85-91.
2
Alpha1-adrenoceptor subtypes and lower urinary tract symptoms.α1肾上腺素能受体亚型与下尿路症状
Int J Urol. 2008 Mar;15(3):193-9. doi: 10.1111/j.1442-2042.2007.01956.x.
3
The evolution of alpha-blockers for the treatment of benign prostatic hyperplasia.用于治疗良性前列腺增生的α受体阻滞剂的演变
Rev Urol. 2006;8 Suppl 4(Suppl 4):S3-9.
4
[Alpha1-adrenoceptor subtype selectivity and organ specificity of silodosin (KMD-3213)].[西洛多辛（KMD-3213）的α1-肾上腺素能受体亚型选择性和器官特异性]
Yakugaku Zasshi. 2006 Mar;126 Spec no.:209-16. doi: 10.1248/yakushi.126.209.
5
Alpha1-adrenergic receptors and their inhibitors in lower urinary tract symptoms and benign prostatic hyperplasia.α1肾上腺素能受体及其抑制剂在膀胱过度活动症和良性前列腺增生中的作用
J Urol. 2004 Mar;171(3):1029-35. doi: 10.1097/01.ju.0000097026.43866.cc.
6
alpha(1)-Adrenoceptor selectivity and the treatment of benign prostatic hyperplasia and lower urinary tract symptoms.α1-肾上腺素能受体选择性与良性前列腺增生和下尿路症状的治疗
Prostate Cancer Prostatic Dis. 2000 Aug;3(2):76-83. doi: 10.1038/sj.pcan.4500410.
7
8
9
KMD-3213, a uroselective and long-acting alpha(1a)-adrenoceptor antagonist, tested in a novel rat model.KMD-3213，一种对尿道有选择性的长效α(1a)肾上腺素能受体拮抗剂，在一种新型大鼠模型中进行了测试。
J Pharmacol Exp Ther. 1999 Oct;291(1):81-91.
Zotero 插件